Read our latest updates & insights

Alvotech and JAMP announce agreement to commercialise five biosimilar products in Canada.

Mundipharma announces commercialisation agreement with Samsung. The agreement grants Mundipharma exclusive commercialisation rights to Samsung’s adalimumab candidate in Taiwan and Hong Kong.

Mundipharma announces commercialisation agreement with Samsung. The agreement grants Mundipharma exclusive commercialisation rights to Samsung’s adalimumab, etanercept, trastuzumab and bevacizumab candidates in Taiwan and Hong Kong.

Coherus exercises option under agreement with Innovent to acquire commercialisation rights to rituximab biosimilar in the US.

Coherus announces licensing agreement with Innovent for the commercialisation of Innovent’s bevacizumab candidate, with plans to file an aBLA in late 2020 or early 2021.

Clover announces it has commenced dosing in Ph III trials of etanercept.

Bio-Thera launches adalimumab biosimilar, Qletli® in China following Nov 2019 approval.

Samsung and AffaMed announce Chinese approval for Phase III trials of eculizumab candidate.

US Court of Appeals affirms US PTAB’s earlier decision, which invalidated three AbbVie patents (8,889,135, 9,017,680 and 9,073,987) as obvious. The initial challenges to these patents were brought by Coherus and Boehringer Ingelheim, who have since settled with AbbVie...

Pfizer launches bevacizumab biosimilar Zirabev® in the US, at a 23% discount to Avastin®.